Chardan Capital Initiates Lion Biotechnologies With Buy

Analysts at Chardan Capital initiated coverage on

with a Buy rating. The target price for Lion Biotechnologies is set to $30. Lion Biotechnologies shares have gained 40.35 percent over the past 52 weeks, while the S&P 500 index has surged 12.25 percent in the same period. Lion Biotechnologies' shares rose 4.23 percent to $12.58 in pre-market trading.